Yahoo
HKSE - Delayed Quote HKD

Dawnrays Pharmaceutical (Holdings) Limited (2348.HK)

0.925 -0.005 (-0.54%)
As of 1:53:19 PM GMT+8. Market Open.
Chart Range Bar
Loading chart for 2348.HK
  • Previous Close 0.930
  • Open 0.925
  • Bid 0.925 x --
  • Ask 0.930 x --
  • Day's Range 0.915 - 0.925
  • 52 Week Range 0.910 - 1.250
  • Volume 208,000
  • Avg. Volume 308,578
  • Market Cap (intraday) 1.392B
  • Beta (5Y Monthly) 0.27
  • PE Ratio (TTM) 5.44
  • EPS (TTM) 0.170
  • Earnings Date --
  • Forward Dividend & Yield 0.06 (6.77%)
  • Ex-Dividend Date Sep 22, 2026
  • 1y Target Est --

Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. It operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. The company offers antibiotics, including pharmaceutical intermediates, bulk medicines, powder for injections, cephalosporin tablets, and other oral solid-dosage-form antibiotics. It also provides system specific medicines for various therapeutic areas, such as cardiovascular systems; anti-HBV, anti-allergic, and digestive systems; urinary systems; anti-hypertensive, antihyperlipidemic, and antiviral; and endocrine system drugs. The company was founded in 1995 and is headquartered in Wan Chai, Hong Kong.

www.dawnrays.com

1,074

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/3/2026, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

2348.HK
19.49%
HANG SENG INDEX (^HSI)
8.56%

1-Year Return

2348.HK
17.46%
HANG SENG INDEX (^HSI)
10.40%

3-Year Return

2348.HK
6.62%
HANG SENG INDEX (^HSI)
32.69%

5-Year Return

2348.HK
17.80%
HANG SENG INDEX (^HSI)
6.34%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    20.30%

  • Return on Assets (ttm)

    3.73%

  • Return on Equity (ttm)

    6.91%

  • Revenue (ttm)

    1.15B

  • Net Income Avi to Common (ttm)

    232.74M

  • Diluted EPS (ttm)

    0.170

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.81B

  • Total Debt/Equity (mrq)

    0.13%

  • Levered Free Cash Flow (ttm)

    190.09M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: